menu
    • menu
    [{"orgOrder":0,"company":"AviadoBio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AVB-PGRN","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ New Enterprise Associates","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ New Enterprise Associates"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AVB-101","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Not Applicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"The Ohio State University Wexner Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AAV-PGRN","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AviadoBio \/ The Ohio State University Wexner Medical Center","highestDevelopmentStatusID":"12","companyTruncated":"AviadoBio \/ The Ohio State University Wexner Medical Center"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"AVB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AviadoBio","amount2":2.23,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AviadoBio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AviadoBio \/ Astellas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by AviadoBio

    Menu

    AviadoBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $2,230.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Astellas & AviadoBio Announce License Agreement of AVB-101 for Frontotemporal Dementia

                            Details : Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $50 million

                            October 08, 2024

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $2,230.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-PGRN

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The Ohio State University Wexner Medical Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASPIRE-FTD Phase 1/2 Trial Opens at Ohio State University Wexner Medical Center

                            Details : AVB-101 (AAV-PGRN) is an investigational gene therapy delivered as a one-time intrathalamic infusion, enabling distribution to brain areas affected by GRN-mutated FTD while limiting systemic exposure.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : AAV-PGRN

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The Ohio State University Wexner Medical Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio Announces First Patient Treated in ASPIRE-FTD Trial Evaluating AVB-101

                            Details : AVB-101 is an investigational gene therapy that contains a correct (non-mutated) version of the GRN gene. It is being evaluated for the treatment of frontotemporal dementia with GRN mutations.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotempor...

                            Details : AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain areas affected by FTD while limiting systemic exposure.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 06, 2023

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Fron...

                            Details : AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels in the brain for the treatment of frontotemporal dementia.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 10, 2023

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising ...

                            Details : In pre-clinical pharmacology studies, AVB-101 administration via intrathalamic injection, in a progranulin-deficient mouse model, demonstrated neuronal specific PGRN brain expression and reduction in disease pathology.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

                            Details : AVB-101 is an investigational AAV gene therapy designed to slow or stop disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore progranulin levels.

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 04, 2022

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and Europea...

                            Details : AVB-101, an investigational, adeno-associated virus gene therapy designed for patients with FTD with mutations in progranulin gene, designed to slow or arrest disease progression by delivering a functional copy of GRN gene throughout CNS to restore norma...

                            Brand Name : AVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 27, 2022

                            Lead Product(s) : AVB-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AviadoBio

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-PGRN

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : New Enterprise Associates

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

                            Details : The funds will be used to advance AviadoBio’s lead program AVB-PGRN, in frontotemporal dementia (FTD) into the clinic, progress its preclinical assets, including for amyotrophic lateral sclerosis (ALS), whilst continuing to expand its industry-leading ...

                            Brand Name : AVB-PGRN

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 02, 2021

                            Lead Product(s) : AVB-PGRN

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : New Enterprise Associates

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth